Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This trial is designed to determine what effects the human body has on the investigational
medicine, ABP 798, and what effects the body has on the investigational medicine after you
have been given it, and if this is comparable to what is seen for the licensed medicine,
rituximab, in patients with CD 20 positive B-cell non Hodgkin lymphoma.
This study will assess if the investigational medicine is safe and effective in treating CD
20 positive B-cell non Hodgkin lymphoma.